孟鲁司特钠对AECOPD患者血清炎性因子水平及肺功能的影响

Effect of montelukast sodium on serum inflammatory factor levels and lung function in patients with AECOPD

目的探讨孟鲁司特钠治疗AECOPD对血清炎性因子及肺功能的影响。方法收集2016年12月~2018年12月期间来我院治疗的AECOPD患者150例进行研究,按照随机数字表法分为两组,研究组和对照组各75例,对照组采用常规治疗,研究组在对照组的基础上采用孟鲁司特钠片治疗,连续治疗2周。比较两组治疗前后肺功能和炎性因子水平。结果治疗后两组肺功能均较治疗前有明显提高,差异有统计学意义(P<0.05),且研究组FEV1、FEV1%、FEV1/FVC明显高于对照组,差异有统计学意义(P<0.05)。治疗后两组炎性因子水平较治疗前有明显降低,差异有统计学意义(P<0.05),且研究组IL-13、TNF-α水平明显低于对照组,差异有统计学意义(P<0.05)。结论孟鲁司特钠治疗AECOPD效果显著,可有效改善临床症状,提高患者的肺功能,降低IL-13、TNF-α因子表达水平,建议临床推广应用。

Objective To investigate the effect of montelukast sodium on serum inflammatory factors and lung function in the treatment of AECOPD. Methods A total of 150 AECOPD patients who were treated in our hospital from December 2016 to December 2018 were enrolled in the study. The patients were divided into two groups according to the random number table, with 75 cases in the study group and 75 cases in the control group. The control group was treated with conventional therapy. The study group was treated with montelukast sodium tablets on the basis of the treatment of the control group. They were continuously treated for 2 weeks. Pulmonary function and inflammatory factor levels were compared before and after treatment in both groups. Results The lung function of the two groups after treatment was significantly higher than that before treatment(P<0.05), and the FEV1, FEV1% and FEV1/FVC of the study group were significantly higher than those of the control group. The difference was statistically significant(P<0.05). The levels of inflammatory factors in the two groups after treatment were significantly lower than those before treatment(P<0.05), and the levels of IL-13 and TNF-α in the study group were significantly lower than those in the control group. The difference between the two groups was statistically significant(P<0.05). Conclusion Montelukast sodium in the treatment of AECOPD has significant efficacy, which can effectively improve clinical symptoms, improve lung function and reduce the expression of IL-13 and TNF-α factors. It is recommended for clinical application.